Eli Lilly and Company reported positive results from a late-stage clinical trial evaluating the combination of its obesity drug Zepbound (tirzepatide) and psoriasis therapy Taltz (ixekizumab) in patients living with moderate-to-severe plaque psoriasis and overweight or obesity.
In the Phase IIIb TOGETHER-PsO study, the dual therapy met its primary endpoint at 36 weeks, with a significantly higher proportion of patients achieving both complete skin clearance and at least 10% body weight reduction compared with those treated with Taltz alone.
Approximately 27.1% of patients receiving the combination reached full skin clearance alongside meaningful weight loss, versus roughly 5.8% in the monotherapy group.
Secondary endpoints also showed improved psoriasis severity scores in the combination arm, reinforcing the potential benefit of addressing metabolic disease and inflammatory skin disease simultaneously. Obesity is a common comorbidity in psoriasis and is known to worsen disease severity and reduce response to certain biologic treatments.
The safety profile of the combined regimen was consistent with the known profiles of both medicines, with no new safety concerns identified.
Zepbound, a dual GIP and GLP-1 receptor agonist, is approved for chronic weight management, while Taltz is an IL-17A inhibitor approved for plaque psoriasis and other inflammatory conditions. The findings suggest that targeting metabolic pathways alongside immune-driven inflammation could represent a new integrated treatment approach for patients with coexisting obesity and psoriasis.
The results add to growing clinical interest in how next-generation metabolic therapies may influence inflammatory disease pathways — a convergence that is increasingly reshaping treatment strategies across immunology and endocrinology.
Also Read